key: cord-1052551-06bs1pgy authors: Kibler, M.; Carmona, A.; Marchandot, B.; Matsushita, K.; Trimaille, A.; Kanso, M.; Dietrich, L.; How-Choong, C.; Odier, A.; Gennesseaux, G.; Schramm, O.; Reydel, A. C.; Kindo, M.; Hoang, M.; Hess, S.; Sato, C.; Ohlmann, S.; Jesel, L.; Morel, O.; Ohlmann, P. title: Risk and severity of COVID-19 and ABO blood group in transcatheter aortic valve patients date: 2020-06-16 journal: nan DOI: 10.1101/2020.06.13.20130211 sha: a09620a6061a609d4a68695d6f2d626dbebc3beb doc_id: 1052551 cord_uid: 06bs1pgy Background: Although cardiovascular disease has been associated with an increased risk of coronavirus disease 2019 (COVID-19), no studies have reported its clinical course in patients with aortic stenosis who had undergone transcatheter aortic valve replacement (TAVR). Several observational studies have found an association between the A blood group and an increased susceptibility to SARS-CoV-2 infection, whereas the O blood group appears to be protective. Objective: To investigate the frequency and clinical course of COVID-19 in a large sample of patients who had undergone TAVR and to determine the associations of the ABO blood group with disease occurrence and outcomes. Methods: Patients who had undergone TAVR between 2010 and 2019 were included in this study and followed-up through the recent COVID-19 outbreak. The main outcomes were the occurrence and severity (hospitalization and/or death) of COVID-19 and their association with the ABO blood group. Results: Of the 1125 patients who had undergone TAVR, 403 (36%) died before January 1, 2020, and 20 (1.8%) were lost to follow-up. The study sample therefore consisted of 702 patients. Among them, we identified 22 cases (3.1%) with COVID-19. Fourteen patients (63.6%) were hospitalized or died of disease. Multivariate analysis identified the A blood group (versus others) as the only independent predictor of COVID-19 in patients who had undergone TAVR (odds ratio [OR] = 6.32; 95% confidence interval [CI] = 2.11-18.92; p=0.001). The A blood group (versus others; OR = 8.27; 95% CI = 1.83-37.43, p=0.006) and a history of cancer (OR = 4.99; 95% CI = 1.64-15.27, p = 0.005) were significantly and independently associated with disease severity (hospitalization and/or death). Conclusions: Patients who had undergone TAVR are vulnerable to COVID-19. The subgroup with the A blood group was especially prone to develop the disease and showed unfavorable outcomes. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020 . . https://doi.org/10.1101 /2020 repurposed as intensive care units (ICUs) (2, 3) . 99 A history of cardiovascular (CV) disease is currently recognized as a risk factor for the 100 occurrence and severity of COVID-19, especially in the elderly (4, 5) . Accordingly, previous 101 studies have indicated that up to 40% of patients who require ICU admission for COVID-19 102 had preexisting congestive heart failure; further, the mortality rate from COVID-19 for 103 patients with preexisting CV disease may be as high as 36% (6) . While there is ample literature 104 to suggest a direct role for a history of heart disease in the susceptibility and severity of 105 COVID-19, its clinical course in patients with valvular disease remains poorly investigated. 106 With a growing number of patients with aortic stenosis being treated with transcatheter aortic 107 valve replacement (TAVR), there is a strong need to investigate this interaction further. 108 Much of the recent focus in COVID-19 research has revolved around biological markers of 109 disease susceptibility and/or severity. The ABO blood group has been shown to affect 110 individual vulnerability to SARS-CoV (7) , hepatitis B virus (8) , Norwalk virus (9) , and 111 Helicobacter pylori infection (10) . Notably, observational studies have found an association 112 between the A blood group and an increased susceptibility to SARS-CoV-2 infection while 113 the O blood group appears to be protective (11) (12) (13) . 114 The present study was undertaken to evaluate the clinical course of COVID-19 in patients 115 with aortic stenosis who had undergone TAVR. We also examined whether the ABO blood 116 group is associated with susceptibility to and severity of (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020 . . https://doi.org/10.1101 /2020 In accordance with WHO technical guidance (14) , patients were considered as confirmed cases 138 of COVID-19 in presence of positive reverse transcriptase-polymerase chain reaction (RT-139 PCR) testing of a nasopharyngeal swab specimen. Because RT-PCR can yield false-negative 140 results, patients with typical symptoms and characteristic imaging findings on chest computed 141 tomography (CT) were classified as confirmed cases (15) . Patients who were hospitalized for 142 or died of COVID-19 were considered to have severe disease. 143 144 Descriptive statistics are expressed as means ± standard deviations for continuous data or as 146 counts (percentages) for categorical variables. Survival curves according to the ABO blood 147 group were plotted by the Kaplan-Meier method (log-rank test) with right censoring at the 148 time of last follow-up (May 8, 2020). The time-to-event was calculated as the time elapsed 149 from January 1, 2020, to the date of the index event (disease onset, hospitalization, or death). 150 Logistic regression models were constructed to evaluate the unadjusted and covariate-adjusted 151 odds ratios (ORs) and 95% confidence intervals (CIs) for the occurrence of COVID-19, 152 COVID-19-related death, and severe COVID-19. Variables adjusted for in the multivariate 153 models were those showing univariate associations at a p value <0.20. Statistical analyses 154 were performed using SPSS, version 17.0 (IBM, Armonk, NY, USA). All tests were two-155 sided, and statistical significance was set as a p value of <0.05. 156 403) or loss to follow-up (n = 20) . Figure 1 depicts the flow of participants through the study. 163 The general patient characteristics (n = 720; mean age: 82 ± 6.9 years; 44% men) are 164 provided in Table 1 . As of January 1, 2020, the all-cause and cardiovascular mortality rates in the study patients 182 were 6.8% and 2.8%, respectively. Compared with patients without COVID-19, those with 183 the disease had significantly higher all-cause mortality (5.6% versus 45.5%, respectively; p 184 <0.001) and hospitalization (1.8% versus 59.1%, respectively; p <0.0001) rates (Table 2) . 185 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Additional analyses were also performed according to blood group A. Patients with the A 198 blood group were more likely to develop COVID-19 compared to those with other blood 199 types (6 versus 1%, respectively; p < 0.0001). In addition, with respect to others blood 200 groups, patients with the A blood group presented more frequently COVID-19-related death 201 (3.4 versus 0%, respectively; p < 0.0001) as well as the combined endpoint of COVID-19-202 related death or hospitalization (4 versus 0.5%, respectively; p < 0.001; Supplemental Table 203 1). 204 205 A history of cancer and the blood type A were significant predictors of COVID-19 in 207 univariate analysis. Multivariate analysis identified the A blood group (versus others) as the 208 only independent predictor of COVID-19 in patients who had undergone TAVR (OR = 6.32; 209 95% CI = 2.11−18.92; p=0.001; Table 3 ). Kaplan-Meier plots of COVID-19-free survival 210 according to the blood group (A versus others) are shown in Figure 2 , panel A. 211 212 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130211 doi: medRxiv preprint Multivariate analysis (Table 4) To our knowledge, this study is the first to specifically investigate the impact of COVID-19 in 221 patients who have undergone TAVR. There are two principal findings from our research. 222 First, patients who had undergone TAVR were at high risk to contract COVID-19. Second, 223 the A blood group was identified as a significant risk factor for both the occurrence and 224 severity of COVID-19. 225 226 The prevalence of COVID-19 in our patients who had undergone TAVR was 3.13%, which is 228 higher than that observed in the general French population (24/10 000 on May 14, 2020) (16) . 229 Whether the increased COVID-19 rate was due to local characteristics of the outbreak in 230 Alsace or to a higher susceptibility conferred by prior CV disease (17) needs further 231 epidemiological study. Moreover, the mortality rate from COVID-19 was 45% in the current 232 investigation. Age, frailty, and a significant burden of comorbidities are possible explanations 233 for the high death toll (18) . Moreover, 63.6% of our patients had severe disease (hospitalization 234 and/or death). Despite these findings, the mechanisms by which CV disease confers 235 susceptibility to COVID-19 remain unclear. Evidence is emerging on the association between 236 aggressive disease and loss of ACE-2 function as a result of its proteolytic cleavage (19) . 237 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06. 13.20130211 doi: medRxiv preprint Under physiological conditions, ACE-2 counteracts the detrimental effects of angiotensin II 238 (20) , which might be overexpressed in patients with CV disease (21) . At sites of endothelial 239 injury, an imbalance between ACE-2 and ACE-1 activity may result in angiotensin II 240 accumulation -which further exacerbates tissue injury and promotes both inflammation and 241 thrombosis (22) . Although our study does not address the role of ACE-2 in the susceptibility to 242 COVID-19 among patients who had undergone TAVR, its involvement is certainly plausible. 243 In the current study, patients who had undergone TAVR and had the A blood group were 246 more prone to develop COVID-19 and were more likely to experience unfavorable outcomes. 247 In a research conducted in 2173 Chinese patients, Zhao et al. (23) showed for the first time that 248 the A blood group was associated with an increased disease susceptibility to COVID-19 while 249 the O group seemed less vulnerable. They also found higher death rates in patients with the A 250 group. A more recent report from the Central Hospital of Wuhan confirmed the increased risk 251 conferred by the A group and the reduced disease susceptibility associated with the O group 252 (12) . Another study connecting the A blood group with an increased risk of contracting 253 COVID-19 is a research on 1599 individuals who underwent SARS-CoV-2 testing in the 254 United States (24) . However, no relation with in-hospital mortality was found. The authors 255 carried these observations a step further with Rh antigen testing and found that its expression 256 could modulate the association of the ABO blood group with disease susceptibility. Similar 257 findings were noticed in our study, albeit limited to the A group. If a subject had the A group 258 and was also Rh+, the patient would have a substantially higher risk of COVID-19, whereas 259 this was not the case for Growing evidence indicates that the A blood group is associated with an increased 261 susceptibility to and severity of COVID-19. The mechanisms beyond this association are 262 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130211 doi: medRxiv preprint unknown but several hypotheses might be raised. It is possible that anti-A antibodies could 263 lead to a decreased interaction of SARS-CoV-2 with its cellular receptor . 264 Interestingly, the A blood group has also been related with an increased risk of CV disease 265 (26) . Numerous biological pathways have been proposed to account for the association 266 between the A blood group and atherothrombosis -including an increased production of 267 soluble intercellular adhesion molecules (27) and/or Von Willebrand factor (vWF) (28) . Other 268 authors have emphasized the significance of vWF cleavage in subjects with the O blood group 269 (29) -an event which may reduce thrombotic risk in SARS-CoV-2-infected individuals (13) . Patients who had undergone TAVR are vulnerable to COVID-19. The subgroup with the A 283 blood group was especially prone to develop the disease and showed unfavorable outcomes. 284 Our results add to the growing literature indicating that the ABO blood group may be a useful 285 laboratory parameter that should be taken into account for risk stratification during clinical 286 work-up of patients with COVID-19. 287 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Sources of funding and support: This study was financially supported by GERCA (Groupe 308 pour 237 l'Enseignement, la prévention et la Recherche Cardiologique en Alsace). 309 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020 . . https://doi.org/10.1101 /2020 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020 . . https://doi.org/10.1101 /2020 426 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 16, 2020. . https://doi.org/10.1101/2020.06.13.20130211 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the prepr The copyright ho this version posted June 16, 2020. . https://doi.org/10.1101/2020.06. 13.20130211 doi: medRxiv preprint ABO blood groups and risk of SARS-CoV-2 Pneumonia :bjh.16845 Global surveillance 350 for COVID-19 caused by human infection with COVID-19 virus: interim guidance Correlation of Chest CT and RT-PCR Testing in 353 COVID-19) in China: A Report of 1014 Cases Are patients with hypertension and diabetes mellitus 358 at increased risk for COVID-19 infection?